Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

N/A
2(66.7%)
Phase 3
1(33.3%)
3Total
N/A(2)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT06702020Active Not Recruiting

VIS Opti-K Vision Improvement for Presbyopes

Role: lead

NCT06597292Not ApplicableNot Yet Recruiting

The VIS Opti-K Low Vision Aid Device Provides Vision Improvement.

Role: lead

NCT06487897Phase 3Recruiting

Phase III Presbyopia Correction Using the VIS Opti-K™ System

Role: lead

NCT06198452Not ApplicableNot Yet Recruiting

Vision Improvement for Patients With Age-Related Macular Degeneration

Role: lead

All 4 trials loaded